The evaluation of PTEN, RB1, and TP53 copy number loss in primary tumor tissue samples during the progression of prostate cancer has established the clinical utility of these tumor suppressor genes as biomarkers for prognosis, response to therapy, and therapeutic resistance (1, 2). This evidence concerns the gene TP53 and prostate carcinoma.